Are Peptides Legal? Indonesia vs USA vs Europe: A Full Comparison

One of the most common questions in the peptide space is also one of the most complicated to answer: are peptides legal where I am? The honest answer is that it depends almost entirely on which peptide, in which country, for what purpose, and through which channel.

This article tries to give a clear, research-based overview of how peptides are classified and regulated in three key regions: Indonesia, the United States, and Europe. It also includes a comparison table so you can see at a glance where different peptides stand across all three.

A note before we begin: regulations change. This article reflects the regulatory landscape as of mid-2026 and is intended for educational purposes. It is not legal advice, and anyone making decisions around peptide use should seek current, country-specific guidance from a qualified professional.

Indonesia's regulatory authority for drugs and food is BPOM, the Badan Pengawas Obat dan Makanan. It is the equivalent of the FDA in the United States or the EMA in Europe.

BPOM classifies pharmaceutical products into four categories:

• Category F - Over-the-counter products
• Category W - Over-the-counter products with specific warnings
• Category G - Prescription-only medicines
• Category O - Narcotics

Most clinical peptides, meaning those used in hospital or medical settings, fall under Category G when registered. This includes insulin and oxytocin, which are BPOM-registered and available through licensed pharmacies with a prescription.

For research and wellness peptides such as BPC-157, TB-500, GHK-Cu, CJC-1295, and Ipamorelin, the situation is different. Indonesia does not have specific regulations that explicitly ban or approve these compounds for personal wellness use. They exist in a regulatory grey area: they are not registered as approved drugs, but they are also not classified as controlled substances or narcotics.

In practical terms, this means that many wellness-oriented peptides are accessible in Indonesia without a formal prescription, but they are not part of any regulated pharmaceutical approval pathway either. This is why product quality, third-party testing, and proper guidance are so important when sourcing these compounds locally.

Semaglutide (sold under brand names such as Ozempic and Wegovy) is registered in Indonesia and classified as a prescription medicine. It is legally available through licensed medical practitioners and registered pharmacies.

The United States Food and Drug Administration (FDA) is one of the most active regulatory bodies in the world when it comes to peptides. With approximately 130 FDA-approved peptide drugs across a wide range of therapeutic areas, the US has a more developed formal approval framework than most countries.

FDA-approved peptide drugs include insulin, semaglutide, tirzepatide, teriparatide, tesamorelin, oxytocin, glucagon, and a growing number of newer compounds across oncology, rare diseases, and endocrinology.

For research and wellness peptides, the FDA has had a turbulent few years. In late 2023, the FDA removed a number of popular research peptides from the list of bulk substances that compounding pharmacies could use, effectively restricting their availability in the US. This included BPC-157, GHK-Cu, TB-500, and others.

However, in February 2026, approximately 14 of these peptides were returned to Category 1 compounding status, meaning licensed compounding pharmacies can once again produce them for patients with a valid prescription from a licensed practitioner. This list includes BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, Selank, Semax, and Thymosin Alpha-1.

These peptides remain unapproved drugs. They are not available over the counter, and their production is limited to licensed compounding pharmacies under practitioner supervision.

On the GLP-1 front, the FDA moved in 2025 and 2026 to end the availability of compounded semaglutide and tirzepatide, as commercial supply has normalised and the shortage justification no longer applied.

The European Medicines Agency (EMA) oversees drug approvals across the European Union. The EMA has approved a range of therapeutic peptides including semaglutide, tirzepatide, teriparatide, insulin products, and oxytocin, broadly mirroring the FDA's approval profile for established clinical peptides.

Europe is generally more conservative than the United States when it comes to compounding. Most EU member states do not have a developed compounding infrastructure comparable to the US 503A/503B compounding pharmacy system. As a result, research peptides such as BPC-157, TB-500, CJC-1295, and GHK-Cu are not formally available through medical channels in most European countries.

Individual EU countries have varying approaches to personal importation and possession of unregistered wellness compounds, but there is no EU-wide approved pathway for the research peptides commonly used in the biohacking and wellness community.

This table covers the most commonly discussed peptides in the wellness, biohacking, recovery, and weight management space. It reflects regulatory status as of mid-2026 and uses the following key:

Compounding status in the USA reflects the February 2026 reclassification returning 14 peptides to Category 1 status. These require a valid prescription from a licensed practitioner.

Several significant peptides and peptide-class compounds are moving through clinical trials and regulatory review globally. Here is where the most talked-about ones currently stand.

Retatrutide (Eli Lilly)

Retatrutide is a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 3 trial data reported in late 2025 showed average weight loss of approximately 28.7% at 68 weeks, surpassing any previously approved compound in this class. An NDA submission to the FDA is projected for late 2026 or early 2027, with potential approval and commercial availability more likely in 2027 to 2028.

CagriSema (Novo Nordisk)

CagriSema is a combination of cagrilintide (an amylin analogue) and semaglutide in a single weekly injection. It is in Phase 3 trials and has demonstrated meaningful weight loss benefits beyond semaglutide alone. An EMA and FDA submission is anticipated in 2026 to 2027.

Survodutide (Zealand Pharma / Boehringer Ingelheim)

Survodutide is a dual glucagon and GLP-1 receptor agonist being studied for both obesity and metabolic-associated steatohepatitis (MASH). It is in Phase 3 trials across multiple indications.

BPC-157 (Clinical Pathway)

While BPC-157 has returned to US compounding status, there are ongoing discussions about a formal clinical development pathway. No NDA has been submitted. If Phase 2 trials currently underway produce clean data, Phase 3 and a potential formal approval pathway could begin within the next three to five years.

For people in Bali and Indonesia, the practical takeaway from all of this is:

Clinical peptides like semaglutide are available in Indonesia through proper prescription channels. If you are interested in semaglutide for weight management, this should be done through a licensed practitioner with appropriate medical assessment and monitoring.

Research and wellness peptides like BPC-157, TB-500, GHK-Cu, CJC-1295, and Ipamorelin exist in a grey area in Indonesia. They are not explicitly banned. They are not formally registered. They are accessible in the wellness market, which is exactly why quality, testing, and professional guidance are so important. Not all products circulating in this market are equal.

Indonesia is actually more permissive in practice than the USA or Europe for research peptides, where formal regulatory frameworks create more barriers. That permissiveness carries a responsibility: the lack of a strict approval process means the burden of quality control falls entirely on the supplier and the individual.

This is why sourcing from a transparent, tested supplier with lab documentation is not optional. It is the only meaningful protection available in the absence of formal regulatory oversight.

Book a Consultation with our team to understand which peptides may be appropriate for your goals, and to access products that come with verified quality documentation.

Order on WhatsApp

Are BPC-157 and TB-500 legal in Indonesia?

They are not formally registered as drugs in Indonesia, nor are they explicitly prohibited as controlled substances. They exist in a regulatory grey area and are accessible in the wellness market. Product quality and sourcing responsibility fall on the individual and supplier rather than a regulatory body.

Can I bring peptides into Indonesia from overseas?

Importing unregistered pharmaceutical compounds into Indonesia can be subject to customs scrutiny. This is another reason why sourcing locally from a transparent supplier is generally preferable.

Is semaglutide legal to use in Indonesia?

Yes. Semaglutide (Ozempic/Wegovy) is registered in Indonesia as a prescription drug and is legally available through licensed medical practitioners and registered pharmacies.

Why does the USA have more approved peptides than Europe?

The US FDA has a large and active compounding pharmacy infrastructure that has historically allowed access to a wider range of peptide compounds under practitioner supervision, even where formal drug approval has not been pursued. Europe's more centralised EMA approval system and more limited compounding culture means fewer peptides have formal pathways outside of full drug approval.

Will more peptides be approved globally in the coming years?

Yes, almost certainly. The GLP-1 class alone has several significant candidates in Phase 3 trials. There is also growing interest in formal clinical pathways for research peptides like BPC-157. The peptide therapeutics market is projected to grow significantly through 2030 and beyond, and regulatory frameworks are evolving to match that growth.

How do I know if a peptide is safe to use in Indonesia?

The regulatory framework in Indonesia does not provide the same level of formal safety review as the FDA or EMA for research peptides. This makes sourcing from a reputable, tested supplier critical. A consultation can also help assess whether a specific peptide is appropriate for your goals and health status.

The regulatory landscape for peptides is genuinely complex and it is moving quickly. What was restricted two years ago may be accessible today. What is in early trials today may be an approved drug in three years. Staying informed matters, and so does working with suppliers and practitioners who take regulatory context seriously.

If you are in Bali and want guidance on what is currently available, what is appropriate for your goals, and how to access it safely, our team is here to help.

Book a Consultation or Order on WhatsApp to get started.

This article is for educational purposes only and does not constitute legal or medical advice. Regulatory status of compounds changes frequently. Always verify current legal status in your jurisdiction before purchasing or using any peptide product. Consult a qualified healthcare professional before starting any peptide protocol.